Mesoblast (ASX:MSB) Total Liabilities: A$312.47 Mil (As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
46 GF Score
Price A$1.89
! 4 Warning Signs
View Full Analysis

What is Mesoblast Total Liabilities?

Mesoblast ASX:MSB -9.38% 46 Total Liabilities is A$312.47 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review.

Mesoblast's Total Liabilities for the quarter that ended in Dec. 2025 was A$312.47 Mil.

Mesoblast's quarterly Total Liabilities declined from Jun. 2025 (A$287.60 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$312.47 Mil).

Mesoblast's annual Total Liabilities increased from Jun. 2023 (A$249.69 Mil) to Jun. 2024 (A$284.33 Mil) and increased from Jun. 2024 (A$284.33 Mil) to Jun. 2025 (A$287.60 Mil).

Mesoblast Total Liabilities Historical Data

* Premium members only.

The historical data trend for Mesoblast's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Total Liabilities Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 213.62 234.93 249.69 284.33 287.60

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 287.60 0.00 312.47 0.00
ASX:MSB
46GF Score
Mesoblast Ltd ASX:MSB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mesoblast's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=157.634+(109.551+16.554
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.84+0.023+0)
=287.60

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=1205.273-917.671
=287.60

Mesoblast's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=192.744+(99.366+16.586
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.763+0.014+0)
=312.47

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1177.372-864.899
=312.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$312.47 Mil mean?
Mesoblast (ASX:MSB) has a Total Liabilities of A$312.47 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mesoblast and its competitors.
Is Mesoblast's Total Liabilities too high?
Mesoblast's current Total Liabilities is A$312.47 Mil. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Total Liabilities compare to VRTX and REGN?
Mesoblast's Total Liabilities of A$312.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mesoblast and its competitors. Mesoblast's current Total Liabilities is A$312.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Total Liabilities of A$312.47 Mil. The current Total Liabilities is A$312.47 Mil. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Total Liabilities is A$312.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score

Get the complete analysis for ASX:MSB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.89
Price